Medication Exposure in Pregnancy Risk Evaluation Program.
about
Prophylaxis and treatment of anthrax in pregnant womenMethods of linking mothers and infants using health plan data for studies of pregnancy outcomesValidity of health plan and birth certificate data for pregnancy research.Trends in elective labor induction for six United States health plans, 2001-2007.Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations.Validation of an algorithm to estimate gestational age in electronic health plan databases.Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries.The prevalence and trends of antiviral medication use during pregnancy in the US: a population-based study of 664,297 deliveries in 2001-2007.Medication exposure in pregnancy risk evaluation program: the prevalence of asthma medication use during pregnancy.Prevalence, trends, and patterns of use of antidiabetic medications among pregnant women, 2001-2007Linking mothers and infants within electronic health records: a comparison of deterministic and probabilistic algorithms.The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy.The future of population-based postmarket drug risk assessment: a regulator's perspective.Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration's Mini-Sentinel program.Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program.Development of a mother-child database for drug exposure and adverse event detection in the Military Health System.Assessing a composite end point for new tocolytics in clinical trials: Data from 4 US integrated delivery networks.Administrative Claims Data Versus Augmented Pregnancy Data for the Study of Pharmaceutical Treatments in Pregnancy.Opportunities and Challenges in Using Epidemiologic Methods to Monitor Drug Safety in the Era of Large Automated Health Databases
P2860
Q28383774-E5EE648E-B9BA-44A5-8060-ED78C372216CQ30618089-0DF31518-2F6F-4516-94DE-6619F9BBBAFEQ34323736-59D93CF1-8618-4CBB-8959-C43A49FEC45AQ34535001-0FD45879-D428-41B0-8392-676C1D5F9161Q34807301-CB3E4D47-2A17-41F8-B9F8-128DA8A3800EQ36816458-3FCDF389-B0F8-4024-8F6F-3149F94504BBQ37026000-EA080FDD-A852-4BAD-BEC8-3C547A740ADFQ37179568-5D13AA47-AA71-4D91-B3D6-5B593C5A4868Q37231125-39B5CE02-1F62-4CE0-A72C-E5810EEB3481Q37262870-3952DFE7-3AED-4032-BEC3-0ECC5D84C374Q38269456-57717235-9A4D-4177-B3DB-1A8C99C266F1Q38853715-DE46D1DE-2BD8-49BA-9881-8C0197DB89BEQ39406884-32F04752-67DF-4C45-9386-FCC476854770Q39767363-AE19C6B7-02FC-4F4E-BCC4-DC271D1C74B0Q40233944-4522205B-1866-40A5-BE85-F01933D400B6Q41125596-4E197416-6B80-4DD6-B0D6-DED2263051C5Q47190995-3E40472A-EF24-45D4-8B25-A4E32AD040DFQ49333326-5454CFAA-F9FE-4C28-ADA1-B339FFD6F203Q57608720-FA979C6D-D6B7-4B66-AEE0-819E58B4EBD6
P2860
Medication Exposure in Pregnancy Risk Evaluation Program.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Medication Exposure in Pregnancy Risk Evaluation Program.
@ast
Medication Exposure in Pregnancy Risk Evaluation Program.
@en
type
label
Medication Exposure in Pregnancy Risk Evaluation Program.
@ast
Medication Exposure in Pregnancy Risk Evaluation Program.
@en
prefLabel
Medication Exposure in Pregnancy Risk Evaluation Program.
@ast
Medication Exposure in Pregnancy Risk Evaluation Program.
@en
P2093
P2860
P1476
Medication Exposure in Pregnancy Risk Evaluation Program.
@en
P2093
David H Smith
Inna Dashevsky
Judy A Staffa
Katherine Haffenreffer
Kimberly Lane
Marsha A Raebel
Pamala A Pawloski
Pamela E Scott
Richard Platt
P2860
P2888
P304
P356
10.1007/S10995-011-0902-X
P577
2012-10-01T00:00:00Z